These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 30552836

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases.
    Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, Yao Y, Fiorentino D.
    PLoS One; 2012; 7(1):e29161. PubMed ID: 22235269
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis.
    Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, De Luna N, Lleixà C, Díaz-Manera J, Rojas-García R, Castellví I, Martínez MA, Grau JM, Selva-O'Callaghan A, Illa I.
    Arthritis Res Ther; 2017 Jul 24; 19(1):174. PubMed ID: 28738907
    [Abstract] [Full Text] [Related]

  • 27. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.
    Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM.
    Arthritis Rheum; 2009 Jun 24; 60(6):1815-24. PubMed ID: 19479879
    [Abstract] [Full Text] [Related]

  • 28. Mitochondrial morphology and MAVS-IFN1 signaling pathway in muscles of anti-MDA5 dermatomyositis.
    Jiang Y, Liu Y, Zhao Y, Zheng Y, Yu M, Deng J, Hao H, Zhang W, Wang Z, Yuan Y.
    Ann Clin Transl Neurol; 2021 Mar 24; 8(3):677-686. PubMed ID: 33576578
    [Abstract] [Full Text] [Related]

  • 29. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis.
    Elst EF, Klein M, de Jager W, Kamphuis S, Wedderburn LR, van der Zee R, Albani S, Kuis W, Prakken BJ.
    Arthritis Rheum; 2008 Feb 24; 58(2):547-55. PubMed ID: 18240224
    [Abstract] [Full Text] [Related]

  • 30. What more can we learn from muscle histopathology in children with dermatomyositis/polymyositis?
    Wargula JC, Lovell DJ, Passo MH, Bove KE, Santangelo JD, Levinson JE.
    Clin Exp Rheumatol; 2006 Feb 24; 24(3):333-43. PubMed ID: 16870106
    [Abstract] [Full Text] [Related]

  • 31. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.
    Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, Crowson CS, Ernste F, Gillespie EB.
    Arthritis Rheum; 2012 Dec 24; 64(12):4078-86. PubMed ID: 22886447
    [Abstract] [Full Text] [Related]

  • 32. Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM).
    Civatte M, Schleinitz N, Krammer P, Fernandez C, Guis S, Veit V, Pouget J, Harlé JR, Pellissier JF, Figarella-Branger D.
    Neuropathol Appl Neurobiol; 2003 Dec 24; 29(6):546-52. PubMed ID: 14636161
    [Abstract] [Full Text] [Related]

  • 33. Involvement of Type I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis.
    Gallay L, Fermon C, Lessard L, Weiss-Gayet M, Viel S, Streichenberger N, Corpet A, Mounier R, Gitiaux C, Mouchiroud G, Chazaud B.
    Neurology; 2022 May 24; 98(21):e2108-e2119. PubMed ID: 35351794
    [Abstract] [Full Text] [Related]

  • 34. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease.
    Kuriyama Y, Shimizu A, Kanai S, Oikawa D, Motegi SI, Tokunaga F, Ishikawa O.
    Sci Rep; 2021 Nov 30; 11(1):23146. PubMed ID: 34848794
    [Abstract] [Full Text] [Related]

  • 35. MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis.
    Xu D, Huang CC, Kachaochana A, Morgan GA, Bonaldo MF, Soares MB, Costa F, Sarwark J, Sredni ST, Pachman LM.
    J Rheumatol; 2016 Jan 30; 43(1):161-8. PubMed ID: 26628598
    [Abstract] [Full Text] [Related]

  • 36. Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis.
    Covert LT, Prinz JA, Swain-Lenz D, Dvergsten J, Truskey GA.
    Rheumatology (Oxford); 2024 Sep 01; 63(SI2):SI240-SI248. PubMed ID: 38317053
    [Abstract] [Full Text] [Related]

  • 37. Dermatomyositis and type 1 interferons.
    Greenberg SA.
    Curr Rheumatol Rep; 2010 Jun 01; 12(3):198-203. PubMed ID: 20425524
    [Abstract] [Full Text] [Related]

  • 38. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.
    Varsani H, Charman SC, Li CK, Marie SK, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith AM, Jacques TS, Lundberg IE, Minetti C, Nennesmo I, Rushing EJ, Sallum AM, Sewry C, Pilkington CA, Holton JL, Wedderburn LR, UK Juvenile Dermatomyositis Research Group.
    Ann Rheum Dis; 2015 Jan 01; 74(1):204-10. PubMed ID: 24064003
    [Abstract] [Full Text] [Related]

  • 39. Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis.
    Sallum AM, Marie SK, Wakamatsu A, Sachetti S, Vianna MA, Silva CA, Kiss MH.
    J Rheumatol; 2004 Apr 01; 31(4):801-7. PubMed ID: 15088312
    [Abstract] [Full Text] [Related]

  • 40. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
    Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, Lu X, Wang GC.
    J Rheumatol; 2015 Jun 01; 42(6):979-87. PubMed ID: 25877505
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.